mopidamol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
1838 13665-88-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • mopidamol
  • rapenton
  • RA-233
A phosphodiesterase inhibitor which inhibits platelet aggregation. Formerly used as an antineoplastic.
  • Molecular weight: 421.50
  • Formula: C19H31N7O4
  • CLOGP: 0.20
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 4
  • TPSA: 142.20
  • ALOGS: -2.54
  • ROTB: 11

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.620 Moderate 0.72
caco2-efflux Caco-2 efflux ratio (BA/AB) 31.550 Moderate 0.72
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 5.636 10^-6 cm/s Moderate 0.72
dh-clint Dog hepatocyte intrinsic clearance 8.670 uL/min/10^6 cells Moderate 0.72
dppb Dog plasma protein binding (% unbound) 34.470 % Moderate 0.72
fcs-ppb Fetal calf serum protein binding (% unbound) 61.200 % Moderate 0.72
herg hERG pIC50 4.613 pIC50 Moderate 0.72
hh-clint Human hepatocyte intrinsic clearance 6.561 uL/min/10^6 cells Moderate 0.72
hlm-clint Human liver microsomal intrinsic clearance 7.015 uL/min/mg protein Moderate 0.72
hppb Human plasma protein binding (% unbound) 34.830 % Moderate 0.72
kinase-safety-class ACVR2A,ACVR2B,AURKA,AURKB,AXL,BRAF,CAMK2B,CAMK2D,CDK1,CDK19,CDK3,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK1,MAP3K21,MAPK7,MAPK9,MARK4,NTRK2,PDK2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 37
kinase-selectivity-class BRAF,CDK16,MAP3K21,MAPK11,TEK 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 2.559 Moderate 0.72
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 17.947 Moderate 0.72
mh-clint Mouse hepatocyte intrinsic clearance 27.290 Moderate 0.72
mppb Mouse plasma protein binding (% unbound) 33.440 Moderate 0.72
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 25.351 Moderate 0.72
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 46.720 % Moderate 0.72
rat-kpuu-brain Rat brain Kpuu 0.011 % Moderate 0.72
rh-clint Rat hepatocyte intrinsic clearance 48.417 uL/min/10^6 cells Moderate 0.72
rh-fuinc Rat hepatocyte fraction unbound in incubation 75.420 % Moderate 0.72
rppb Rat plasma protein binding (% unbound) 39.510 % Moderate 0.72
solubility-dd Solubility at pH 7.4 in DMSO 194.089 uM Moderate 0.72

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
MeSH PA D000970 Antineoplastic Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 7.85 Basic
pKa2 6.0 Basic
pKa3 2.08 Basic
pKa4 0.26 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
C0026523 UMLSCUI
CHEBI:135682 CHEBI
CHEMBL2106769 ChEMBL_ID
D009012 MESH_DESCRIPTOR_UI
26172 PUBCHEM_CID
4337 INN_ID
4Q0IWP8B8O UNII

Pharmaceutical products:

None